32 Results

People

  1. Lesokhin
    Lesokhin
  2. Usmani
    Usmani
  3. Mailankody
    Mailankody
  4. Giralt
    Giralt
  5. Shah
    Shah
  6. Shah
    Shah
  7. Dogan
    Dogan
  8. Farzana
    Farzana
  9. Hassoun
    Hassoun
  10. Hultcrantz
    Hultcrantz

Groups

  1. Hematologic Malignancies, Division of (24)
  2. Center for Hematologic Malignancies (23)
  3. Department of Medicine (23)
  4. Myeloma (19)
  5. Hematologic Malignancies Research (14)
  6. Bone Marrow Transplant (8)
  7. Sloan Kettering Institute Postdocs (7)
  8. CTCR Scholars (6)
  9. Survivorship Research (6)
  10. GME, Medicine (4)
  1. "b-cell maturation antigen"
Formats
  1. Journal Article (20)
  2. Review (6)
  3. Meeting Abstract (4)
  4. Editorial (1)
  5. Guidelines (1)
Groups
  1. Hematologic Malignancies, Division of (24)
  2. Center for Hematologic Malignancies (23)
  3. Department of Medicine (23)
  4. Myeloma (19)
  5. Hematologic Malignancies Research (14)
  6. Bone Marrow Transplant (8)

More Groups

People
  1. Alexander Lesokhin (9)
  2. Saad Usmani (9)
  3. Sham Mailankody (8)
  4. Sergio Giralt (6)
  5. Gunjan Shah (5)
  6. Urvi Shah (5)

More People

Years
  1. 2025 (4)
  2. 2024 (7)
  3. 2023 (10)
  4. 2022 (4)
  5. 2021 (2)
  6. 2020 (2)

More Years

Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (5)
  2. Blood (3)
  3. Transplantation and Cellular Therapy (3)
  4. Best Practice and Research: Clinical Haematology (2)
  5. Blood Cancer Journal (2)
  6. New England Journal of Medicine (2)

More Publications

Publishers
  1. Elsevier Inc. (11)
  2. Nature Publishing Group (4)
  3. American Society of Hematology (3)
  4. Elsevier Science, Inc. (2)
  5. Massachusetts Medical Society (2)
  6. Adis International Ltd (1)

More Publishers

Results (32)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Chimeric antigen receptor T cell therapy for myeloma: Where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert panel opinion from the American Society for Transplantation and Cellular Therapy
    Guidelines

    Anderson, L. D. Jr; Dhakal, B.; Jain, T.; Oluwole, O. O.; Shah, G. L.; Sidana, S.; Perales, M. A.; Pasquini, M. C.
    Transplantation and Cellular Therapy (2024)

    Fulltext@MSK | Save
  • Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial
    Journal Article

    Nooka, A. K.; Cohen, A. D.; Lee, H. C.; Badros, A.; Suvannasankha, A.; Callander, N.; Abdallah, A. O.; Trudel, S.; Chari, A.; Libby, E. N.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab in relapsed or refractory multiple myeloma: Phase 2 MagnetisMM-3 trial results
    Journal Article

    Lesokhin, A. M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Miles Prince, H.; Niesvizky, R.; Rodrίguez-Otero, P.; Martinez-Lopez, J.; Koehne, G.; Touzeau, C.; more...
    Nature Medicine (2023)

    Fulltext@MSK | Save
  • Driving CARs to new places: Locally produced BCMA CAR T cells to treat multiple myeloma
    Editorial

    Sjöstrand, M.; Sadelain, M.
    Haematologica (2023)

    Fulltext@MSK | Save
  • Teclistamab versus real-world physician's choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
    Journal Article

    Krishnan, A.; Nooka, A. K.; Chari, A.; Garfall, A. L.; Martin, T. G.; Nair, S.; Lin, X.; Qi, K.; Londhe, A.; Pei, L.; more...
    Journal of Comparative Effectiveness Research (2023)

    Fulltext@MSK | Save
  • Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: A multi-institution experience
    Journal Article

    Kourelis, T.; Bansal, R.; Berdeja, J.; Siegel, D.; Patel, K.; Mailankody, S.; Htut, M.; Shah, N.; Wong, S. W.; Sidana, S.; more...
    Transplantation and Cellular Therapy (2023)

    Fulltext@MSK | Save
  • Comparative efficacy of teclistamab versus physician's choice of therapy in the long-term follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS clinical trials in patients with triple-class exposed relapsed or refractory multiple myeloma
    Journal Article

    Mateos, M. V.; Chari, A.; Usmani, S. Z.; Goldschmidt, H.; Weisel, K.; Qi, K.; Londhe, A.; Nair, S.; Lin, X.; Pei, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save